IRRAS Future Growth

Future criteria checks 2/6

IRRAS is forecast to grow earnings and revenue by 96.4% and 84.7% per annum respectively.

Key information

96.4%

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	15.9%
Revenue growth rate	84.7%
Future return on equity	n/a
Analyst coverage	Low
Last updated	03 Jan 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:4Z7 - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	249	-30	N/A	N/A	1
12/31/2023	165	-101	N/A	N/A	1
6/30/2023	43	-196	-195	-192	N/A
3/31/2023	43	-193	-197	-193	N/A
12/31/2022	40	-167	-179	-176	N/A
9/30/2022	37	-164	-160	-157	N/A
6/30/2022	32	-141	-133	-129	N/A
3/31/2022	27	-131	-134	-129	N/A
12/31/2021	22	-136	-138	-131	N/A
9/30/2021	18	-131	-131	-123	N/A
6/30/2021	14	-135	-134	-125	N/A
3/31/2021	10	-140	-139	-129	N/A
12/31/2020	7	-136	-141	-133	N/A
9/30/2020	8	-134	-151	-144	N/A
6/30/2020	7	-139	-159	-152	N/A
3/31/2020	7	-147	-166	-152	N/A
12/31/2019	5	-151	-169	-154	N/A
9/30/2019	2	-165	-159	-138	N/A
6/30/2019	1	-171	-146	-125	N/A
3/31/2019	0	-160	-130	-116	N/A
12/31/2018	6	-139	-112	-97	N/A
9/30/2018	7	-112	-103	-95	N/A
6/30/2018	18	-78	-90	-82	N/A
3/31/2018	18	-67	-78	-68	N/A
12/31/2017	12	-61	-65	-54	N/A
9/30/2017	11	-48	-53	-35	N/A
12/31/2016	N/A	-32	N/A	-18	N/A
12/31/2015	N/A	-13	N/A	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4Z7 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4Z7 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4Z7 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4Z7's revenue (84.7% per year) is forecast to grow faster than the German market (4.7% per year).

High Growth Revenue: 4Z7's revenue (84.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4Z7's Return on Equity is forecast to be high in 3 years time

IRRAS Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB Provides Revenue Guidance for the Year 2022

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Insufficient new directors

Insufficient new directors

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

Insufficient new directors

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Insufficient new directors

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

Insufficient new directors

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

New 90-day low: €0.62

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Revenue misses expectations

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: €0.81

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Revenue misses expectations

Third quarter 2020 earnings released: kr0.47 loss per share

New 90-day high: €0.66

First half earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies